Wanhuida Intellectual Property

Jianhui Li of Wanhuida Intellectual Property explains how China addresses the question of whether the features of an administration process limit a patented product and distinguish it from prior art

Yue Guan of Wanhuida Intellectual Property reports on a case in China that has implications for the drafting of compound patents incorporating Markush claims

Feng Zheng and Xiaoyang Yang of Wanhuida outline the various defence mechanisms patentees have at their disposal when facing infringement accusations in China

Tiejun Tang, Yuming Wang, and Jianhui Li of Wanhuida Intellectual Property discuss the evolving landscape in China around ‘offering for sale’, with reference to a high-profile Supreme People’s Court case involving a patented drug

Xiaohui Wu of Wanhuida Intellectual Property reports on a ruling by the Supreme People’s Court of China that emphasises that the determination of common knowledge in the assessment of inventiveness should be incontrovertible

Yue Guan of Wanhuida Intellectual Property analyses a decision by the China National Intellectual Property Administration on the validity of a pulmonary hypertension drug and the implications for pharmaceutical patentees